Capvizr
THE DEAL, AT A GLANCE

LifeMine Therapeutics

From the announcement
01Who is involvedBacked by fungiFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02What happenedLifeMine Therapeutics raised $263M Series CFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
03Why it mattersLifeMine Therapeutics has raised $263M to advance LIFE-001 and a broader transplantation and immunology pipeline, with the financing anchored by a $188M Series E…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

LifeMine Therapeutics · Financing Record

Explore source-linked visual explanations for LifeMine Therapeutics. Unsupported claims are withheld while source review continues.

Record 9838 · Recorded date: Needs review

What it does

Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.

Open record 9838 →

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime